Janney Montgomery Scott LLC Lowers Holdings in DaVita Inc. $DVA

Janney Montgomery Scott LLC decreased its stake in DaVita Inc. (NYSE:DVA) by 59.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,327 shares of the company’s stock after selling 14,853 shares during the quarter. Janney Montgomery Scott LLC’s holdings in DaVita were worth $1,471,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of DVA. UMB Bank n.a. boosted its position in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after purchasing an additional 76 shares in the last quarter. National Pension Service raised its holdings in shares of DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after acquiring an additional 84 shares during the last quarter. Y.D. More Investments Ltd acquired a new stake in shares of DaVita in the first quarter valued at approximately $35,000. NewEdge Advisors LLC increased its holdings in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of DaVita in the first quarter valued at approximately $83,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on DVA shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a report on Wednesday. Truist Financial set a $148.00 price objective on DaVita in a research report on Friday, August 8th. Barclays lowered their price objective on DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a research report on Thursday. Bank of America lowered their price target on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Finally, Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $155.25.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

DaVita Price Performance

DaVita stock opened at $123.91 on Friday. DaVita Inc. has a 1-year low of $123.13 and a 1-year high of $179.60. The stock has a market cap of $8.86 billion, a PE ratio of 12.18, a P/E/G ratio of 0.89 and a beta of 1.13. The stock’s fifty day moving average is $133.26 and its two-hundred day moving average is $139.25.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period last year, the firm earned $2.00 earnings per share. DaVita’s quarterly revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.